Asen A.
- Country
- Bulgaria
- Department
- BG10003: Rheumatology
Research Overview
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- Efficacy and Safety Evaluation of Bimekizumab Versus Risankizumab in Adults with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-Blind Study
- Efficacy and Safety of Subcutaneous Guselkumab in Active Psoriatic Arthritis: A Phase 3b Randomized, Double-blind, Placebo-controlled Study
Data & Insights
Has run more than one trial at 106 of 215 partner sites.
Specializations
Rheumatology Focus
This investigator specializes in studying psoriatic arthritis (PsA), with particular emphasis on evaluating novel therapeutic approaches for patients with active disease manifestations.
- Active PsA Management
- Biologic DMARD Research
- Treatment-Resistant PsA
The research encompasses both treatment-naive patients and those with inadequate response to existing therapies.
Therapeutic Development
Focused on investigating innovative biological therapies for autoimmune conditions, with particular attention to new treatment modalities including sonelokimab and guselkumab.
- Novel Biologics Evaluation
- Subcutaneous Administration
- Dosing Optimization
The investigator evaluates various dosing regimens and administration protocols to optimize therapeutic outcomes.
Clinical Assessment
Specializes in measuring therapeutic efficacy through established clinical metrics, particularly focusing on ACR50 response criteria and reduction in disease symptoms.
- Treatment Response Assessment
- Safety Monitoring
- Comparative Efficacy Studies
Employs comprehensive evaluation methods to assess both treatment effectiveness and safety profiles.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.